Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021

Rhea-AI Summary

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) will release its fourth quarter and full year 2020 financial results on February 25, 2021, after market close. A live conference call and webcast will follow at 5:00 PM ET for a discussion on the financial results and business updates. Aerie focuses on ophthalmic therapies for open-angle glaucoma, with products like Rhopressa® and Rocklatan® already in the market. The company continues to explore global expansion and additional ophthalmology treatments.

Positive

• Aerie's product portfolio includes FDA-approved Rhopressa® and Rocklatan®, targeting elevated IOP.
• Company is focused on global expansion and developing more ophthalmic product candidates.

Negative

• None.

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its fourth quarter and full year 2020 financial results will be released after the market closes on Thursday, February 25, 2021. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.

The live webcast and a replay may be accessed by visiting the Company’s website at http://investors.aeriepharma.com. Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (888) 734-0328 (U.S.) or (678) 894-3054 (international) to listen to the live conference call. The conference ID number for the live call is 9047298. Please dial in approximately 10 minutes prior to the call. Telephone replay will be available approximately two hours after the call. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international). The conference ID number for the replay is 9047298. The telephone replay will be available until March 5, 2021.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa^® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa^®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan^® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa^® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan^®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005018/en/

FAQ

When will Aerie Pharmaceuticals announce its Q4 2020 results?

Aerie Pharmaceuticals will announce its Q4 2020 results on February 25, 2021, after market close.

What time will Aerie Pharmaceuticals hold its conference call?

Aerie Pharmaceuticals will hold its conference call at 5:00 PM ET on February 25, 2021.

Where can I access the Aerie Pharmaceuticals financial results webcast?

The webcast can be accessed on Aerie Pharmaceuticals' investor website at http://investors.aeriepharma.com.

What products does Aerie Pharmaceuticals offer for glaucoma treatment?

Aerie Pharmaceuticals offers Rhopressa® and Rocklatan® for the treatment of elevated intraocular pressure in patients with open-angle glaucoma.